MarketCap
Facebook
X
Telegram
Arcus Biosciences EV/EBITDA Ratio | RCUS
Annual EV/EBITDA Ratio Arcus Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.18 | -2.44 | -3.26 | -4.03 | 54.5 | -17 | -4 | -5.04 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.5 | -17 | 1.69 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Reata Pharmaceuticals
RETA
|
1.42 K | - | - | $ 6.29 B |  USA |
 |
ObsEva SA
OBSV
|
-1.92 | - | -15.52 % | $ 10.5 M |  Schweiz |
 |
PolarityTE
PTE
|
0.0431 | - | -0.82 % | $ 1.78 M | USA |
 |
Kronos Bio
KRON
|
0.524 | - | 1.49 % | $ 50.8 M | USA |
 |
Landos Biopharma
LABP
|
-0.743 | - | 0.58 % | $ 144 M | USA |
 |
Myovant Sciences Ltd.
MYOV
|
-3.16 | - | -0.04 % | $ 2.62 B | USA |
 |
Poseida Therapeutics
PSTX
|
-3.48 | - | - | $ 857 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.186 | - | - | $ 231 M | USA |
 |
Trevena
TRVN
|
-0.583 | - | -46.58 % | $ 31.8 M | USA |
 |
Immunovant
IMVT
|
13.9 K | $ 35.73 | 1.65 % | $ 6.52 B | USA |
 |
Virpax Pharmaceuticals
VRPX
|
-0.15 | - | -45.12 % | $ 2.85 M | USA |
 |
Oncorus
ONCR
|
-0.814 | - | -8.54 % | $ 3.19 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
-5.77 | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
-1.39 | - | -2.99 % | $ 2.47 M | USA |
 |
InMed Pharmaceuticals
INM
|
25.4 | $ 15.56 | 13.57 % | $ 64.8 M |  Canada |
 |
Stealth BioTherapeutics Corp
MITO
|
-10.8 | - | - | $ 23.9 M | USA |
 |
Acer Therapeutics
ACER
|
-1.56 | - | 2.71 % | $ 14 M | USA |
 |
Satsuma Pharmaceuticals
STSA
|
-0.268 | - | -0.9 % | $ 36.5 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-3.84 | $ 1.14 | -6.97 % | $ 97.2 M | USA |
 |
SpringWorks Therapeutics
SWTX
|
-16.3 | - | - | $ 3.48 B | USA |
 |
Metacrine
MTCR
|
0.582 | - | - | $ 24.2 M | USA |
 |
Turning Point Therapeutics
TPTX
|
-8.12 | - | -0.13 % | $ 3.73 B | USA |
 |
Infinity Pharmaceuticals
INFI
|
-0.898 | - | -46.98 % | $ 3.57 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-0.728 | - | 31.87 % | $ 1.61 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.142 | - | - | $ 7.46 M |  Israel |
 |
Evelo Biosciences
EVLO
|
-0.456 | - | -14.46 % | $ 27.9 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8.87 | - | -4.8 % | $ 255 M | USA |
 |
Morphic Holding
MORF
|
-8.35 | - | - | $ 2.42 B | USA |
 |
Novan
NOVN
|
-3.01 | - | -24.84 % | $ 2.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-1.28 | - | -15.0 % | $ 3.04 M | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-0.433 | - | -9.21 % | $ 2.55 M | USA |
 |
Albireo Pharma
ALBO
|
-3.46 | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
-20.9 | - | - | $ 2.47 B | Canada |
 |
bluebird bio
BLUE
|
-2.04 | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-113 | - | - | $ 13.6 B | USA |
 |
IGM Biosciences
IGMS
|
-1.38 | - | - | $ 76.9 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
-4.05 | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-101 | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
0.542 | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
-0.383 | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
-1.08 | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
-0.028 | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
0.293 | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
0.288 | - | -1.38 % | $ 46.8 M | USA |
 |
Mirati Therapeutics
MRTX
|
-3.35 | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
-3.18 | - | - | $ 309 M | USA |
 |
Allogene Therapeutics
ALLO
|
-3.13 | $ 0.93 | -11.99 % | $ 205 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
0.956 | - | -37.48 % | $ 476 K | USA |
 |
Epizyme
EPZM
|
-0.12 | - | - | $ 249 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
0.361 | - | -9.72 % | $ 5.89 M | USA |